Cancer cocktail aims to turn inoperable tumors into surgical wins
NCT ID NCT07263360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a mix of immunotherapy (iparomlimab and tuvonralimab), chemotherapy (gemcitabine and oxaliplatin), and a targeted drug (lenvatinib) can shrink bile duct and gallbladder cancers enough to be surgically removed. About 29 adults with locally advanced but potentially resectable cancer will receive up to six cycles of treatment. The main goal is to see how many patients can have complete tumor removal (R0 resection).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and Tuvonralimab (immunotherapy) combined with Gemcitabine, Oxaliplatin, and Lenvatinib (chemotherapy and targeted therapy)
- What this could lead to
- If successful, this combination could shrink tumors enough to allow surgical removal, potentially improving long-term survival for people with bile duct or gallbladder cancer.
- What could go wrong
- This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The combination of drugs can cause significant side effects, and it is not yet known if it will work better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BTC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable